Mankind Pharma acquires Bharat Serums from Advent International for ₹13,630 crore. Learn More
Powered by people and science, BSV stands as a leading biopharmaceutical company in India and across the world.
For over five decades, Bharat Serums & Vaccines Limited (BSV) has been a pioneer in biopharmaceutical innovation, delivering life-saving solutions to millions. Now part of the Mankind Pharma family, BSV continues to shape the future of medicine with a strong focus on improving women’s health, maternal care, fertility, and beyond. Our values of Transparency, Agility, Accountability, and Collaboration, hold us in good stead in every step of our patient journey. Numerous pharmaceutical, biotech, and biological products have been developed since the inception of BSV in 1971.
our principles
Guided by values,

driven by people
Transparency Transparency
We believe in honest communication, fostering an enterprise-wide view in every conversation, and encouraging ongoing, meaningful dialogue.
Agility Agility
By prioritizing resources, reducing complexity, embracing risks, and engaging early, we stay adaptable to deliver impactful solutions.
Accountability Accountability
A performance-driven culture where teams take ownership of KRAs, understand the "Why," and deliver with responsibility and commitment.
BSV at a glance:
Excellence in Numbers
Countries where our products have market share
70+
Countries where our
products have market share
Product patents In India, USA, EU and other countries
15+
Product patents In India,
USA, EU and other countries
Awards for innovation & excellence
40+
Awards for innovation
& excellence
Employees across the globe
2500+
Employees across
the globe
Associates dedicated to R&D
60+
Associates dedicated
to R&D
Market leading brands in Philippines & Germany
13
Market leading brands in
Philippines & Germany
OUR JOURNEY
Shaping global health through the years
2024
2017 - 2024
2012 - 2016
2001 - 2011
1981 - 2000
1971 - 1981
  • Mankind Pharma completes landmark acquisition of BSV
  • Setting New Benchmarks in Patient Outcomes
  • BSV has achieved remarkable milestones, shaping its journey as a global biopharmaceutical leader. In 2017, Advent International acquired a majority stake in BSV, setting the stage for accelerated growth. Strategic acquisitions, including TTK Healthcare's Human Pharma business and Malaysian entities Firstline Pharmaceuticals and Genomicks, solidified BSV’s expertise in the IVF segment.
  • On a Fast Track to Excellence
  • BSV has been recognized as the fastest-growing biotech company by Frost & Sullivan and ranked among the Top 10 biopharmaceutical companies by Biospectrum.
  • The company launched innovative treatments for sepsis and acute pancreatitis and expanded its product portfolio to 62 domestic and 32 global offerings. BSV also completed clinical trials for a flagship product, further advancing its position in the industry.
  • With ISO certifications for quality, health, safety, and environmental management, BSV's Ambernath plant received EU GMP and Brazil ANVISA approvals.
  • In addition, Advent International’s acquisition of a majority stake and the introduction of infertility solutions have propelled BSV’s growth, with the company now ranked among the top 50 pharma companies by AIOCD AWACS.
  • Expanding Our Global Footprint
  • During this decade, BSV made significant strides in global expansion and innovation. The company secured EU and US FDA approvals for its facility in Germany, establishing a strong international presence.
  • BSV began operations in the Philippines, which has since become a wholly-owned subsidiary, and expanded its manufacturing capabilities with a facility in Ambernath, near Mumbai.
  • Patent filing efforts were initiated, with 15 product patents filed both in India and globally. Additionally, BSV launched a recombinant hormone to stimulate ovarian follicular growth, addressing infertility issues and reinforcing its commitment to women’s health.
  • R&D Takes Center Stage
  • This period marked a significant shift for BSV as research and development took center stage. The company launched its indigenously-developed Plasma Fractions, earning R&D recognition from the Department of Scientific & Industrial Research, Government of India.
  • BSV also made a pioneering move with the launch of India’s first immunoglobulin against Pseudomonas infection, showcasing its commitment to addressing critical healthcare challenges through innovation and R&D excellence.
  • An Exciting Start
  • BSV's journey began with a strong foundation of innovation and compassion. Late Dr. Vinod Daftary opened the company’s first blood bank, marking a significant milestone in healthcare.
  • The company also launched an injection to help women with Rh-negative blood groups successfully become mothers, addressing a crucial need in maternal health. BSV expanded its reach by exporting polyclonal sera and commissioned a plant in Thane. Additionally, the launch of indigenously-developed Plasma Fractions showcased BSV's commitment to advancing healthcare solutions from within India.
Transforming health across
key therapy areas
Women’s Health
Women’s
Health
Assisted Reproductive Technology (ART)
Assisted
Reproductive
Technology (ART)
Critical Care
Critical Care
Emergency Medicine
Emergency
Medicine
Strong presence across India and key emerging markets
Strong presence
across India and key emerging markets
With a strong global presence and subsidiaries in the Philippines, Germany, and the US, BSV ensures life-saving therapies are accessible to millions worldwide.
70
Covered Markets
530+
Registrations
220
Registrations in Pipeline

Central & South America

Through collaborations and deep understanding of local healthcare challenges, we continue to expand our reach to meaningful difference in every market we serve.

  • Existing Presence

    Covered Markets

    • Peru
    • Guatemala
    • Colombia
    • Dominican Republic
    • Honduras
    • Brazil
    • Chile
    • Bolivia

Africa / Middle East

Through collaborations and deep understanding of local healthcare challenges, we continue to expand our reach to meaningful difference in every market we serve.

  • Existing Presence

    covered markets

    • Algeria
    • Kenya
    • Ghana
    • Uganda
    • Nigeria
    • Zambia
    • Tanzania
    • Yemen
    • Iraq
    • Francophone Countries

Russia & CIS

Through collaborations and deep understanding of local healthcare challenges, we continue to expand our reach to meaningful difference in every market we serve.

  • Existing Presence

    covered markets

    • Russia
    • Ukraine
    • Uzbekistan
    • Kyrgyzstan
    • Kazakhstan

South East Asia

Through collaborations and deep understanding of local healthcare challenges, we continue to expand our reach to meaningful difference in every market we serve.

  • Existing Presence

    Covered Markets

    • Philippines
    • Vietnam
    • Thailand
    • Myanmar
    • Malaysia
    • Bangladesh
    • Sri Lanka
    • Cambodia
    • Pakistan
  • Existing Presence

    Emerging Markets

    • Chile
    • Peru
    • Colombia

Germany

BSV BioScience GmbH is a 100% subsidiary of the Indian pharmaceutical enterprise Bharat Serums & Vaccines Ltd. The German branch manufactures and markets biological pharmaceutical active ingredients for different therapeutic areas.

Philippines

BSV BioScience Phils., Inc. is a wholly owned subsidiary of Bharat Serums and Vaccines Ltd., in India where it is considered to be one of the most respected and fastest growing biopharmaceutical companies.

Central & South America
Through collaborations and deep understanding of local healthcare challenges, we continue to expand our reach to meaningful difference in every market we serve.
Covered Markets
  • Peru
  • Guatemala
  • Colombia
  • Dominican Republic
  • Honduras
  • Brazil
  • Chile
  • Bolivia
Africa / Middle East
Through collaborations and deep understanding of local healthcare challenges, we continue to expand our reach to meaningful difference in every market we serve.
Covered Markets
  • AlgeriaUK
  • Kenya
  • Ghana
  • Uganda
  • Nigeria
  • Zambia
  • Tanzania
  • Yemen
  • Iraq
  • Francophone Countries
Russia & CIS
Through collaborations and deep understanding of local healthcare challenges, we continue to expand our reach to meaningful difference in every market we serve.
Covered Markets
  • Russia
  • Ukraine
  • Uzbekistan
  • Kyrgyzstan
  • Kazakhstan
South East Asia
Through collaborations and deep understanding of local healthcare challenges, we continue to expand our reach to meaningful difference in every market we serve.
Covered Markets
  • Philippines
  • Vietnam
  • Thailand
  • Myanmar
  • Malaysia
  • Bangladesh
  • Sri Lanka
  • Cambodia
  • Pakistan
Germany
BSV BioScience GmbH is a 100% subsidiary of the Indian pharmaceutical enterprise Bharat Serums & Vaccines Ltd. The German branch manufactures and markets biological pharmaceutical active ingredients for different therapeutic areas.
Philippines
BSV BioScience Phils., Inc. is a wholly owned subsidiary of Bharat Serums and Vaccines Ltd., in India where it is considered to be one of the most respected and fastest growing biopharmaceutical companies.
*BSV Bioscience GmbH & BSV Bioscience Philippines are subsidiaries
Research & Development
Fueling innovation
through science
BSV’s foundation is built on groundbreaking research and innovation, setting new benchmarks in patient outcomes and healthcare solutions.
  • State-of-the-art R&D Centers
  • 60+ Scientists
  • Strong IP Capabilities
  • Niche R&D Product Pipeline
Fueling innovation through science
BSV PATENTS
We identify and tackle
complex challenges.
Patent
status
5
Patents Cited
2
Patents Granted
3
Patents Filed
17
Patents in Force
Countries
5 filed
Brazil, China, Saudi Arabia, USA,
South Korea
5 granted
Australia, Eurasia, Canada, Europe, South Africa
BSV PATENTS
BSV drives innovation through a focus on IP and advanced R&D to develop and secure patents.
Key Innovation
Trinbelimab

The world’s first marketed recombinant Anti Rh(o)-D Immunoglobulin, is a pioneering New Biological Entity (NBE) developed by BSV to prevent sensitization in Rh negative mothers to prevent complications of hemolytic disease in newborn babies. Proudly patented globally, it embodies India's vision of innovating in India, making in India for the world.

Since its launch in 2021, Trinbelimab has protected over 2.6 million Rh negative mothers. Winner of Modi Prix Galien 2024 for the Best Biotechnology Product, Trinbelimab sets the global benchmarks in maternal care, reflecting BSV’s commitment to improving
health worldwide.

India’s first Biological & generic advancements
Key Innovation
India’s first in Biological & Generic Advancements

Indias first to introduce groundbreaking biological advancements such as Urinary Trypsin Inhibitor, Equine Rabies Ig, and Anti-Thymocyte Globulin. In addition, our Novel Drug Delivery System (NDDS) includes the revolutionary Propofol Emulsion.

We also take pride in being the first to launch generics in India, including High Pure HMG under biologicals, Recombinant FSH and Recombinant HCG in biotech, and cutting-edge NDDS solutions like Generic Implant and Liposomal Amphotericin B.

India’s first in Biological & Generic Advancements
Key Innovation
BSV bringing World’s first Biotech & NDDS Advancements

We are proud to be at the forefront of global healthcare innovation with our "1st in the World" achievements. In the field of biotech, we introduced groundbreaking solutions like Monoclonal Anti D and Monoclonal Tetanus.

Additionally, our advancements in the Novel Drug Delivery System (NDDS) include the revolutionary Amphotericin B - Emulsion Formulation, setting a new benchmark in pharmaceutical innovation.

BSV bringing World’s first Biotech & NDDS Advancements
Manufacturing Facilities
World-class facilities
with global standards
All
Ambernath, India Facility
Ambernath, India Facility
Maharashtra
With 5 dedicated injectable formulation lines and 2 API manufacturing lines, it produces cutting-edge injectables for India and emerging markets.

Human & equine biological, thrombolytic and urinary hormone products

EU GMP, ANVISA Brazil

Aachen, Germany Facility
Aachen, Germany Facility
Germany
A US FDA approved plant manufacturing Active Pharmaceutical Ingredients (APIs) and fertility hormones.

Biological pharmaceuticals and fertility hormones.

German GMOP and US FDA-approved

Excellence,
Acknowledged Globally
2024 - Great Place to Work
BSV certified as a Great Place To
Work in India and Germany
2024 - The Economic Times
BSV recognised as the
Best Organization for Women
2024 - Prix Galien India
Trinbelimab (Anti-D) recognised
as “Best Biotechnology Product”
2024 - The Economic Times
Sanjiv Navangul - MD & CEO,
recognised as Impactful CEO

of The Year
2024 - 10th NATHealth Arogya Bharat Summit
BSV’s “Leprosy Elimination Action Programme (LEAP)" wins Special Award in CSR category
2022 - The Economic Times
BSV recognised one of the
Best Sustainable Organization
2022 - The Economic Times
BSV‘s Anti-D recognised as
Best Healthcare Brand
about mankind pharma
Innovating in India for
India and the world
As part of the Mankind Pharma family, BSV remains committed to redefining healthcare with innovative therapies that improve lives in India and across the world.
Innovating in India for India and the world